RBC Capital analyst Gregory Renza maintained a Buy rating on Viracta Therapeutics (VIRX – Research Report) yesterday and set a price target of $6.00. The company’s shares closed yesterday at $0.83.
According to TipRanks, Renza is a 5-star analyst with an average return of 18.7% and a 47.62% success rate. Renza covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals, Agios Pharma, and Alpine Immune Sciences.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Viracta Therapeutics with a $7.67 average price target.
VIRX market cap is currently $32.4M and has a P/E ratio of -0.63.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Viracta Therapeutics (VIRX) Company Description:
Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The firms activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The company was founded on February 10, 1998 and is headquartered in South San Francisco, CA.
Read More on VIRX:
